| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
Purity: =99.38%
Embelin is a naturally occurring quinone compound that was isolated from the Japanese herb Ardisia. It has anti-tumor and anti-inflammatory properties, and it also functions as a powerful and cell-permeable inhibitor of XIAP (X-linked inhibitor of apoptosis), with an IC50 value of 4.1 μM in cell-free assays.
| Targets |
5-LO (IC50 = 0.06 μM); mPGES-1 (IC50 = 0.2 μM); XIAP (IC50 = 4.1 μM)
|
||
|---|---|---|---|
| ln Vitro |
Embelin from the Japanese Ardisia herb is a small-molecular inhibitor that binds to the XIAP BIR3 domain with which Smac and caspsase-9 bind. Embelin has IC50 values of 3.7 and 5.7 μM and inhibits PC-3 and LNCap cell growth in a dose-dependent manner. While Embelin's toxicity in normal PrEC and WI-38 cells is much lower, with IC50 values of 20.1 μM and 19.3 μM, respectively. When PC-3 cells are treated for 48 hours with 25 and 50 μM of embelin, 30% and 75% of the cells die, which is an increase of about 3 and 9 times more than in untreated cells.[1] Embelin selectively inhibits 5-lipoxygenase (5-LO) and Microsomal prostaglandin E2 synthase-1 (mPGES-1) with IC50 values of 0.06 and 0.2 mM, respectively, to suppress the biosynthesis of eicosanoids.[2]
|
||
| ln Vivo |
|
||
| Enzyme Assay |
Fluorescence polarization experiments are performed in Dynex 96-well, black, round-bottom plates. A final volume of 125 L is created by adding a 5 μL sample of Embelin dilutions in DMSO, preincubated XIAP BIR3 protein (0.06 M), and the N terminus of a Smac peptide (SM7F) (0.01 M) in the assay buffer. Both the bound peptide control (equivalent to 0% inhibition) and the free peptide control (equivalent to 100% inhibition) were used in each assay. The bound peptide control contained XIAP BIR3 protein and SM7F. To achieve equilibrium, the plates were combined and incubated for 3 hours at room temperature.
|
||
| Cell Assay |
The MTT-based assay, which uses Cell Proliferation Reagent WST-1 in accordance with the manufacturer's instructions, is used to measure cell growth. Cells (5000 cells/well) are grown in medium containing 10% FBS and different concentrations of Embelin. WST-1 is added to each well and incubated for 1-3 hours at 37 °C four to five days later. A plate reader is used to measure absorbance at 450 nm with a correction at 650 nm.
|
||
| Animal Protocol |
|
||
| References | |||
| Additional Infomation |
Embelin is a member of the class of dihydroxy-1,4-benzoquinones that is 2,5-dihydroxy-1,4-benzoquinone which is substituted by an undecyl group at position 3. Isolated from Lysimachia punctata and Embelia ribes, it exhibits antimicrobial, antineoplastic and inhibitory activity towards hepatitis C protease. It has a role as a hepatitis C protease inhibitor, an antimicrobial agent, an antineoplastic agent and a plant metabolite.
Embelin has been reported in Embelia schimperi, Ardisia paniculata, and other organisms with data available. |
| Molecular Formula |
C17H26O4
|
|
|---|---|---|
| Molecular Weight |
294.39
|
|
| Exact Mass |
294.183
|
|
| Elemental Analysis |
C, 69.36; H, 8.90; O, 21.74
|
|
| CAS # |
550-24-3
|
|
| Related CAS # |
|
|
| PubChem CID |
3218
|
|
| Appearance |
Yellow to orange solid powder
|
|
| Density |
1.131
|
|
| Boiling Point |
431.9±45.0 °C at 760 mmHg
|
|
| Melting Point |
145-146 ºC
|
|
| Flash Point |
229.1±25.2 °C
|
|
| Vapour Pressure |
0.0±2.3 mmHg at 25°C
|
|
| Index of Refraction |
1.538
|
|
| LogP |
5.7
|
|
| Hydrogen Bond Donor Count |
2
|
|
| Hydrogen Bond Acceptor Count |
4
|
|
| Rotatable Bond Count |
10
|
|
| Heavy Atom Count |
21
|
|
| Complexity |
432
|
|
| Defined Atom Stereocenter Count |
0
|
|
| SMILES |
O([H])C1C(C([H])=C(C(C=1C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])=O)O[H])=O
|
|
| InChi Key |
IRSFLDGTOHBADP-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C17H26O4/c1-2-3-4-5-6-7-8-9-10-11-13-16(20)14(18)12-15(19)17(13)21/h12,18,21H,2-11H2,1H3
|
|
| Chemical Name |
2,5-dihydroxy-3-undecylcyclohexa-2,5-diene-1,4-dione
|
|
| Synonyms |
Embelic acid; NSC91874; NSC91874; Embelin; NSC 91874; Emberine
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (8.49 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.49 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3969 mL | 16.9843 mL | 33.9685 mL | |
| 5 mM | 0.6794 mL | 3.3969 mL | 6.7937 mL | |
| 10 mM | 0.3397 mL | 1.6984 mL | 3.3969 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT06042647 | Active Recruiting |
Drug: 0.01% Halobetasol Drug: 0.045% Tazarotene |
Psoriasis Vulgaris | Dermatology Consulting Services, PLLC |
July 13, 2023 | Phase 4 |
| NCT03926299 | Active Recruiting |
Device: FotonaSmooth SP® Spectro laser device Drug: Clobetasol propionate 0.05% ointment |
Chronic Skin Disease Vulvar Lichen Sclerosus |
Prof. Dr. Volker Viereck | July 15, 2019 | Not Applicable |
| NCT01893567 | Completed | Drug: Clobex Spray | Plaque Psoriasis | Galderma R&D | July 2013 | Phase 4 |
| NCT00852761 | Completed | Drug: Olux-E Foam Drug: Clobex lotion |
Plaque-Type Psoriasis | Stiefel, a GSK Company | March 2009 | Phase 4 |
| NCT00715975 | Completed | Drug: halobetasol Drug: clobetasol |
Psoriasis | Azidus Brasil | July 2008 | Phase 2 Phase 3 |
 |
|---|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA